Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
- Agreement clears path for launch of Jubbonti and Wyost on May 31, 2025 or earlier under certain circumstances
- Jubbonti and Wyost are first and only FDA-approved biosimilars to and interchangeable with Prolia* and Xgeva*
- Anticipated launch further strengthens Sandoz biosimilar portfolio and advances growth strategy